[1]
|
Leiter, A., Veluswamy, R.R. and Wisnivesky, J.P. (2023) The Global Burden of Lung Cancer: Current Status and Future Trends. Nature Reviews Clinical Oncology, 20, 624-639. https://doi.org/10.1038/s41571-023-00798-3
|
[2]
|
Wang, Q., Gümüş, Z.H., Colarossi, C., Memeo, L., Wang, X., Kong, C.Y. and Boffetta, P. (2023) SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. Journal of Thoracic Oncology, 18, 31-46. https://doi.org/10.1016/j.jtho.2022.10.002
|
[3]
|
Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? The Lancet, 357, 539-545. https://doi.org/10.1016/s0140-6736(00)04046-0
|
[4]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674. https://doi.org/10.1016/j.cell.2011.02.013
|
[5]
|
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y. and Li, Y. (2021) Inflammation and Tumor Progression: Signaling Pathways and Targeted Intervention. Signal Transduction and Targeted Therapy, 6, Article No. 263. https://doi.org/10.1038/s41392-021-00658-5
|
[6]
|
魏智民, 孙玉发, 李刚, 等. 癌症相关性炎症与肿瘤微环境相关研究进展[J]. 中国肿瘤临床, 2018, 45(21): 1117-1121.
|
[7]
|
de Visser, K.E. and Joyce, J.A. (2023) The Evolving Tumor Microenvironment: From Cancer Initiation to Metastatic Outgrowth. Cancer Cell, 41, 374-403. https://doi.org/10.1016/j.ccell.2023.02.016
|
[8]
|
Arneth, B. (2019) Tumor Microenvironment. Medicina, 56, Article 15. https://doi.org/10.3390/medicina56010015
|
[9]
|
Nagarsheth, N., Wicha, M.S. and Zou, W. (2017) Chemokines in the Cancer Microenvironment and Their Relevance in Cancer Immunotherapy. Nature Reviews Immunology, 17, 559-572. https://doi.org/10.1038/nri.2017.49
|
[10]
|
Bremnes, R.M., Al-Shibli, K., Donnem, T., Sirera, R., Al-Saad, S., Andersen, S., Stenvold, H., Camps, C. and Busund, L. (2011) The Role of Tumor-Infiltrating Immune Cells and Chronic Inflammation at the Tumor Site on Cancer Development, Progression, and Prognosis: Emphasis on Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 6, 824-833. https://doi.org/10.1097/jto.0b013e3182037b76
|
[11]
|
Brenner, D.R., McLaughlin, J.R. and Hung, R.J. (2011) Previous Lung Diseases and Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLOS ONE, 6, e17479. https://doi.org/10.1371/journal.pone.0017479
|
[12]
|
Azad, N., Rojanasakul, Y. and Vallyathan, V. (2008) Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species. Journal of Toxicology and Environmental Health, Part B, 11, 1-15. https://doi.org/10.1080/10937400701436460
|
[13]
|
Zhang, J. and Veeramachaneni, N. (2022) Targeting Interleukin-1β and Inflammation in Lung Cancer. Biomarker Research, 10, Article No. 5. https://doi.org/10.1186/s40364-021-00341-5
|
[14]
|
Que, H., Fu, Q., Lan, T., Tian, X. and Wei, X. (2022) Tumor-Associated Neutrophils and Neutrophil-Targeted Cancer Therapies. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1877, Article 188762. https://doi.org/10.1016/j.bbcan.2022.188762
|
[15]
|
Lord, E.M., Penney, D.P., Sutherland, R.M. and Cooper, R.A. (1979) Morphological and Functional Characteristics of Cells Infiltrating and Destroying Tumor Multicellular Spheroids in Vivo. Virchows Archiv B Cell Pathology, 31, 103-116. https://doi.org/10.1007/bf02889928
|
[16]
|
彭译漫, 罗香梦, 陈婧瑶. 肿瘤微环境代谢的研究进展及免疫治疗新策略[J]. 四川大学学报(医学版), 2023, 54(3): 505-509.
|
[17]
|
Kitamura, T., Qian, B. and Pollard, J.W. (2015) Immune Cell Promotion of Metastasis. Nature Reviews Immunology, 15, 73-86. https://doi.org/10.1038/nri3789
|
[18]
|
Heinrich, E.L., Walser, T.C., Krysan, K., Liclican, E.L., Grant, J.L., Rodriguez, N.L. and Dubinett, S.M. (2011) The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis. Cancer Microenvironment, 5, 5-18. https://doi.org/10.1007/s12307-011-0089-0
|
[19]
|
Semenza, G.L. (2009) Defining the Role of Hypoxia-Inducible Factor 1 in Cancer Biology and Therapeutics. Oncogene, 29, 625-634. https://doi.org/10.1038/onc.2009.441
|
[20]
|
Yoo, Y., Christensen, J. and Huang, L.E. (2011) HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function. Cancer Research, 71, 1244-1252. https://doi.org/10.1158/0008-5472.can-10-2360
|
[21]
|
Gomes, M., Teixeira, A.L., Coelho, A., et al. (2014) The Role of Inflammation in Lung Cancer. Advances in Experimental Medicine and Biology, 816, 1-23.
|
[22]
|
Greten, F.R. and Grivennikov, S.I. (2019) Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity, 51, 27-41. https://doi.org/10.1016/j.immuni.2019.06.025
|
[23]
|
Mantovani, A., Sozzani, S., Locati, M., Allavena, P. and Sica, A. (2002) Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2 Mononuclear Phagocytes. Trends in Immunology, 23, 549-555. https://doi.org/10.1016/s1471-4906(02)02302-5
|
[24]
|
Denk, D. and Greten, F.R. (2022) Inflammation: The Incubator of the Tumor Microenvironment. Trends in Cancer, 8, 901-914. https://doi.org/10.1016/j.trecan.2022.07.002
|
[25]
|
Bent, R., Moll, L., Grabbe, S. and Bros, M. (2018) Interleukin-1 Beta—A Friend or Foe in Malignancies? International Journal of Molecular Sciences, 19, Article 2155. https://doi.org/10.3390/ijms19082155
|
[26]
|
Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z., Egan, L.J., Kagnoff, M.F. and Karin, M. (2004) IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell, 118, 285-296. https://doi.org/10.1016/j.cell.2004.07.013
|
[27]
|
Saito, A., Horie, M. and Nagase, T. (2018) TGF-β Signaling in Lung Health and Disease. International Journal of Molecular Sciences, 19, Article 2460. https://doi.org/10.3390/ijms19082460
|
[28]
|
Feng, X. and Derynck, R. (2005) Specificity and Versatility in TGF-β Signaling through Smads. Annual Review of Cell and Developmental Biology, 21, 659-693. https://doi.org/10.1146/annurev.cellbio.21.022404.142018
|
[29]
|
Hao, Y., Baker, D. and ten Dijke, P. (2019) TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences, 20, Article 2767. https://doi.org/10.3390/ijms20112767
|
[30]
|
Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M., Powderly, J., Heist, R., Sequist, L.V., Smith, D.C., Leming, P., Geese, W.J., Yoon, D., Li, A. and Brahmer, J. (2018) Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results from the CA209-003 Study. Journal of Clinical Oncology, 36, 1675-1684. https://doi.org/10.1200/jco.2017.77.0412
|
[31]
|
Choi, Y.L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., Ishikawa, Y., Kimura, H., Mitsudomi, T., Tanio, Y. and Mano, H. (2010) EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. New England Journal of Medicine, 363, 1734-1739. https://doi.org/10.1056/nejmoa1007478
|
[32]
|
Blumenschein, G.R. (2011) Developmental Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs, 30, 1802-1811. https://doi.org/10.1007/s10637-011-9750-1
|
[33]
|
Smith, C.J., Perfetti, T.A. and King, J.A. (2006) Perspectives on Pulmonary Inflammation and Lung Cancer Risk in Cigarette Smokers. Inhalation Toxicology, 18, 667-677. https://doi.org/10.1080/08958370600742821
|